Vector-borne diseases (VBDs) pose significant public health challenges in India, with their management requiring a multifaceted approach. This article aims to provide a comprehensive review of the prevalence and strategies for controlling these diseases.
India, with its diverse climatic and geographical conditions, serves as a breeding ground for various vectors, leading to a high incidence of VBDs. Malaria, Dengue, and Chikungunya are the most common, contributing to significant morbidity and mortality. As per the National Vector Borne Disease Control Programme (NVBDCP), India reported approximately 331,058 malaria cases and 101,192 Dengue cases in 2019, demonstrating the scale of the problem.
The management of VBDs in India is fraught with challenges. These include a lack of comprehensive surveillance systems, inadequate diagnostic facilities, and limited access to effective treatment in remote areas. Moreover, the resistance of vectors to insecticides and parasites to drugs has further complicated the issue.
India's strategy for controlling VBDs involves an integrated approach that includes disease surveillance, early detection, prompt treatment, and vector control measures. The NVBDCP has implemented various programs like the National Malaria Control Program and the National Dengue Control Program to combat these diseases. The government is also promoting community participation and inter-sectoral coordination for effective VBD management.
Despite the challenges, significant progress has been made in managing VBDs in India. However, there is a need for more robust surveillance systems, improved diagnostic facilities, and effective treatment strategies. Healthcare professionals play a crucial role in this endeavor, and their active participation in disease control programs can significantly reduce the burden of VBDs in India.
1.
Can Concurrent Boost Safely Shorten Breast Cancer Radiation?
2.
Study shows supervised exercise improves strength, physical performance in patients with advanced breast cancer
3.
Ultrasound bras; HPV and thyroid cancer; language minimizing adverse events.
4.
In patients with advanced lung cancer, cemiplimab combined with chemotherapy extends life and enhances quality of life.
5.
The FDA Approves the New Frontline Aggressive ALL Regimen.
1.
Hematopoietic Stem Cell Exhaustion in Blood Disorders
2.
Lymphomatoid Papulosis: What You Need to Know
3.
The Growing Crisis of Aplastic Anemia: A Call for Action
4.
Importance of Early Detection in Hematology
5.
Clonal Hematopoiesis Dynamics and Future Hematologic Outcomes
1.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
2.
International Cancer Conference
3.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
4.
Asian Symposium on Advancement in Hematology and Oncology
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Navigating the Complexities of Ph Negative ALL - Part X
2.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part V
3.
Pazopanib Takes Center Stage in Managing Renal Cell Carcinoma - Part IV
4.
Iron Deficiency Anemia: Ferric Maltol As a New Treatment Option- Further Discussion on A New Perspective
5.
Lung Cancer: Risk Factors and Prevention
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation